3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Conditions
Glioblastoma
4
Gliosarcoma
3
Brain Neoplasms
3
Neoplasms
2
Glioma
2
Recurrence
1
Brain Stem Neoplasms
1
Interventions
Temozolomide
19
Bevacizumab
14
Irinotecan
12
Carboplatin
10
Cyclophosphamide
9
Radiosurgery
8
Lomustine
8
Radiotherapy
7
pembrolizumab
6
Vincristine
6
Topotecan
6
Drug Therapy
6
Surgical Procedures, Operative
5
Etoposide
5
Doxorubicin
5
Cisplatin
5
3-Iodobenzylguanidine
5
trametinib
4
Metformin
4
Gemcitabine
4
Dexamethasone
4
Blood Specimen Collection
4
poly ICLC
3
dabrafenib
3
Vorinostat
3
Trastuzumab
3
Therapeutics
3
Radiation
3
Paclitaxel
3
Observation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
rindopepimut
×
CNS
×
Clear all
NCT01498328
2020-02-17
ReACT
Celldex Therapeutics
Phase 2
Completed
127 enrolled
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled